Neurological Surgery 脳神経外科51巻4号

2023年07月発行

特集 下垂体腫瘍診療の新フェーズ—変革期の疫学・診断・治療における必須知識 Ⅱ 下垂体腫瘍の疫学・遺伝・病態

下垂体神経内分泌腫瘍（下垂体腺腫）の疫学・遺伝・病態

著者： 鈴木幸二¹ 田原重志²

所属機関： ¹国立病院機構横浜医療センター脳神経外科 ²日本医科大学脳神経外科

ページ範囲：P.593 - P.606

Point
・2017年以降のWHO脳腫瘍分類の改訂や高齢化などの時代背景の影響も加味しながら，下垂体神経内分泌腫瘍の疫学に関して概説した．
・分子病理学的研究が進むにつれ，下垂体神経内分泌腫瘍は3つの転写因子（PIT1，Tpit，SF1）に基づく系統分類が可能になった．
・下垂体神経内分泌腫瘍の発生原因としての分子病理学的背景は非常に多様性に富んでおり，症例の多くは依然として発症機序が不明である．

参考文献

1）Ezzat S, et al：The prevalence of pituitary adenomas：a systematic review. Cancer 101：613-619, 2004

2）Daly AF, et al：High prevalence of pituitary adenomas：a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91：4769-4775, 2006

3）The Committee of Brain Tumor Registry of Japan：Brain Tumor Registry of Japan（1984-2000）. Neurol Med Chir（Tokyo）49 Suppl：PS1-PS96, 2009

4）The Committee of Brain Tumor Registry of Japan：Brain Tumor Registry of Japan（2005-2008）. Neurol Med Chir（Tokyo）57（Suppl 1）：9-102, 2017

5）Japan Neurosurgical Society：Report of Japan Neurosurgery Registry（2015-2017）. Neurol Med Chir（Tokyo）59（Spec）：13-81, 2019

6）Nishioka H, et al：The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26：349-355, 2015

7）Mete O, et al：Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 31：900-909, 2018

8）Osamura RY, et al：Pathology, pathogenesis and therapy of growth hormone（GH）-producing pituitary adenomas：technical advances in histochemistry and their contribution. Acta Histochem Cytochem 42：95-104, 2009

9）WHO Classification of Tumours Editorial Board：WHO Classification of Tumours Endocrine and Neuroendocrine Tumours（5th ed.）. International Agency for Research on Cancer, Lyon, 2022

10）Gubbiotti MA, Baloch Z：An overview of pituitary neuroendocrine tumors（PitNET）and algorithmic approach to diagnosis. Adv Anat Pathol 30：79-83, 2023

11）Asa SL, et al：Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33：6-26, 2022

12）Inomoto C, et al：Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms. Brain Tumor Pathol 38：183-188, 2021

13）Asa SL, et al：Genomics and epigenomics of pituitary tumors：what do pathologists need to know? Endocr Pathol 32：3-16, 2021

14）Vasilev V, et al：Clinical and molecular update on genetic causes of pituitary adenomas. Horm Metab Res 52：553-561, 2020

15）Coopmans EC, Korbonits M：Molecular genetic testing in the management of pituitary disease. Clin Endocrinol（Oxf）97：424-435, 2022

16）Tatsi C, Stratakis CA：The genetics of pituitary adenomas. J Clin Med 9：30, 2019　doi：10.3390/jcm9010030

17）Dénes J, Korbonits M：The clinical aspects of pituitary tumour genetics. Endocrine 71：663-674, 2021

18）Schöfl C, et al：Frequency of AIP gene mutations in young patients with acromegaly：a registry-based study. J Clin Endocrinol Metab 99：E2789-E2793, 2014　doi：10.1210/jc.2014-2094

19）Georgitsi M, et al：Aryl hydrocarbon receptor interacting protein（AIP）gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol（Oxf）69：621-627, 2008

20）Daly AF, et al：AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. Endocr Connect 8：338-348, 2019

21）Tichomirowa MA, et al：High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165：509-515, 2011

22）Chang M, et al：Genetic and epigenetic causes of pituitary adenomas. Front Endocrinol（Lausanne）11：596554, 2021　doi：10.3389/fendo.2020.596554

23）Daly AF, et al：Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas：an international collaborative study. J Clin Endocrinol Metab 95：E373-E383, 2010　doi：10.1210/jc.2009-2556

24）Caimari F, et al；International FIPA consortium：Risk category system to identify pituitary adenoma patients with AIP mutations. J Med Genet 55：254-260, 2018

25）Naves LA, et al：Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein（AIP）gene. Arq Bras Endocrinol Metabol 54：761-767, 2010

26）Joshi K, et al：Resistant paediatric somatotropinomas due to AIP mutations：role of pegvisomant. Horm Res Paediatr 90：196-202, 2018

27）Personnier C, et al：Clinical features and treatment of pediatric somatotropinoma：case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr 75：392-402, 2011

28）Dutta P, et al：Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation-positive child. J Clin Endocrinol Metab 104：3539-3544, 2019

29）Yang I, et al：Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 134：720-726, 1996

30）Fougner SL, et al：Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol（Oxf）76：96-102, 2012

31）Larkin S, et al：Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 168：491-499, 2013

32）Hayward BE, et al：Imprinting of the G（s）alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 107：R31-36, 2001

33）Gadelha MR, et al：Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24：238-246, 2013

34）Buchfelder M, et al：Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary 1：181-185, 1999

35）Zhou Y, et al：Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma. Mol Cell Endocrinol 386：16-33, 2014

36）Reincke M, et al：Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet 47：31-38, 2015

37）Ma ZY, et al：Recurrent gain-of-function USP8 mutations in Cushing's disease. Cell Res 25：306-317, 2015

38）Perez-Rivas LG, et al：The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing Cushing's disease. J Clin Endocrinol Metab 100：E997-E1004, 2015　doi：10.1210/jc.2015-1453

39）Hayashi K, et al：The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Eur J Endocrinol 174：213-226, 2016

40）Faucz FR, et al：Somatic USP8 gene mutations are a common cause of pediatric Cushing disease. J Clin Endocrinol Metab 102：2836-2843, 2017

41）Losa M, et al：Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas. Endocrine 63：240-246, 2019

42）Wanichi IQ, et al：Cushing's disease due to somatic USP8 mutations：a systematic review and meta-analysis. Pituitary 22：435-442, 2019

43）Bujko M, et al：USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status. Eur J Endocrinol 181：615-627, 2019

44）Martins CS, et al：USP8 mutations and cell cycle regulation in corticotroph adenomas. Horm Metab Res 52：117-123, 2020

45）Jian FF, et al：Inhibition of ubiquitin-specific peptidase 8 suppresses adrenocorticotropic hormone production and tumorous corticotroph cell growth in AtT20 cells. Chin Med J（Engl）129：2102-2108, 2016

46）Albani A, et al：The USP8 mutational status may predict long-term remission in patients with Cushing's disease. Clin Endocrinol（Oxf）89：454-458, 2018

47）Bruns C, et al：SOM230：a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor（SRIF）receptor binding and a unique antisecretory profile. Eur J Endocrinol 146：707-716, 2002

48）Neou M, et al：Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37：123-134.e5, 2020　doi：10.1016/j.ccell.2019.11.002

49）Chen J, et al：Identification of recurrent USP48 and BRAF mutations in Cushing's disease. Nat Commun 9：3171, 2018　doi：10.1038/s41467-018-05275-5

50）Li C, et al：Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun 11：2506, 2020　doi：10.1038/s41467-020-16052-8

51）da Silva-Junior RMP, et al：Integrating methylome and transcriptome signatures expands the molecular classification of the pituitary tumors．J Clin Endocrinol Metab 108：1452-1463, 2023

52）Srirangam Nadhamuni V, Korbonits M：Novel insights into pituitary tumorigenesis：genetic and epigenetic mechanisms. Endocr Rev 41：821-846, 2020

53）Spada A, et al：Pituitary tumors：genetic and molecular factors underlying pathogenesis and clinical behavior. Neuroendocrinology 112：15-33, 2022

54）国際ヒトエピゲノムコンソーシアム：エピゲノム研究を病気の治療に役立てるために　エピゲノムと疾患．　https://crest-ihec.jp/public/epigenome_mal.html（2023年3月10日アクセス）

55）国立がん研究センター：がん情報サービス．　https://ganjoho.jp/public/index.html（2023年3月10日アクセス）